David Beckham’s IM 8 longevity supplement brand has secured US $1 billion in growth financing from General Catalyst’s Customer Value Fund, marking a significant infusion for the company’s expansion plans.
Funding details and expected impact
The financing, announced by Prenetics Global – the parent company co‑founded by Beckham – will cover up to 70 % of IM 8’s marketing spend while the brand retains full creative control. General Catalyst will receive a capped share of income generated from customer cohorts financed by the deal.
According to a partner at the fund, Adit Swarup, “IM 8 is a category‑defining consumer health business, and the underlying cohort economics are among the strongest we’ve seen across the Customer Value Fund portfolio.” He added that the cohort retention data is “highly consistent across geographies, subscription tenors, and product lines,” setting new industry benchmarks for direct‑to‑consumer health.
Related: DSM-Firmenich and Nous to launch Koncentra globally
Since its launch in December 2024, IM 8 has reported sales of more than 50 million servings and is delivering roughly 200 000 servings daily across 43 countries. The company’s revenue has already surpassed US $200 million, with a recent month (June 2026) showing preliminary, unaudited revenue of about US $17 million.
Growth outlook and product pipeline
Prenetics Global estimates it entered the financing round with roughly US $139.7 million in cash. The new capital will fund a broad marketing push that includes digital performance ads, offline and connected‑TV media, athlete partnerships, brand activations, and content production.
IM 8 plans to launch additional products in the coming year, including an IM 8 Hydration line in Q4 2026 and a premium gummies line slated for Q1 2027. Both offerings aim to broaden the portfolio beyond its two flagship drinks: Daily Ultimate Essentials, a 90‑ingredient nutritional foundation, and Daily Ultimate Longevity, which features a proprietary five‑complex system targeting the biological roots of aging.
Related: How to get a medical marijuanas card in Washington online
The company also continues to expand its clinical evidence base. Two randomized controlled trials on gut health and longevity are currently underway, highlighting the brand’s focus on scientific validation.
With the new financing, IM 8 expects to accelerate its trajectory toward a billion‑dollar annual revenue scale within the next few years. The brand’s full‑year 2026 revenue guidance has been raised to US $210–220 million, and it forecasts an annualized run‑rate of US $300 million by the end of 2026, rising to over US $400 million in 2027.
